SCHEMBL2107224

SCHEMBL2107224

NC(=O)CC(=O)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
REN P00797 2/20 0.51
LMNA P02545 1/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TSHR P16473 1/20 0.47
GRIN2D O15399 1/20 0.47
GRIN3B O60391 1/20 0.47
GRIN1 Q05586 1/20 0.47
GRIN2A Q12879 1/20 0.47
GRIN2B Q13224 1/20 0.47
GRIN2C Q14957 1/20 0.47
GRIN3A Q8TCU5 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9518741 0.90 ALDH1A1 (0.62) ALDH1A1NPSR1NPC1RAB9ALMNA
SCHEMBL1128948 0.88 NPC1 (0.64) ALDH1A1NPSR1NPC1RAB9AREN
SCHEMBL1128947 0.84 ALDH1A1 (0.56) ALDH1A1NPSR1NPC1RAB9AREN
SCHEMBL3856362 0.83 FDPS (0.42) ALDH1A1NPSR1NPC1RAB9AREN
SCHEMBL7135592 0.81 NPC1 (0.79) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL5031217 0.81 YAP1 (0.46) ALDH1A1LMNATDP1
SCHEMBL2939974 0.81 ALOX5 (0.58) ALDH1A1NPSR1NPC1RAB9AREN
SCHEMBL4210846 0.80 LMNA (0.53) ALDH1A1NPSR1NPC1RAB9AREN
SCHEMBL1386528 0.79 LMNA (0.57) ALDH1A1NPSR1NPC1RAB9AREN
Carbamic Acid SCHEMBL6466030 0.79 LMNA (0.57) ALDH1A1NPSR1NPC1RAB9AREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3662089-A1 METHOD FOR SEPARATING PALLADIUM FROM OTHER METAL ELEMENTS PRESENT IN AN AQUEOUS NITRIC PHASE USING SPECIFIC MALONAMIDES AS EXTRACTANTS Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2020-06-10 EP claimed
EP-2030966-B1 BENZYLIDENE MALONAMIDE AND SALT THEREOF, ULTRAVIOLET RAY ABSORBENT, AND AGENT FOR EXTERNAL APPLICATION TO THE SKIN SHISEIDO CO LTD (JP) 2013-01-02 EP claimed
CN-101472881-A Benzylidene malonamide and salt thereof, ultraviolet ray absorbent, and agent for external application to the skin SHISEIDO CO LTD (JP) 2009-07-01 CN claimed
CN-118290285-A Method for synthesizing amide 中国石油化工股份有限公司 2024-07-05 CN disclosed
US-8841309-B2 Substituted pyrazines and their use in the treatment of disease BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-09-23 US disclosed
US-20140088097-A1 HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-03-27 US disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
CN-101472881-A Benzylidene malonamide and salt thereof, ultraviolet ray absorbent, and agent for external application to the skin SHISEIDO CO LTD (JP) 2009-07-01 CN disclosed
WO-2007144981-A1 BENZYLIDENE MALONAMIDE AND SALT THEREOF, ULTRAVIOLET RAY ABSORBENT, AND AGENT FOR EXTERNAL APPLICATION TO THE SKIN SHISEIDO COMPANY, LTD. (JP) 2007-12-21 WO disclosed
US-20040073038-A1 Process of preparing paroxetine and intermediates for use therein SPURCOURT LIMITED (GB) 2004-04-15 US disclosed
EP-1362032-A2 PROCESS OF PREPARING PAROXETINE AND INTERMEDIATES FOR USE THEREIN Spurcourt Limited (GB) 2003-11-19 EP disclosed
WO-2002068416-A2 PROCESS OF PREPARING PAROXETINE AND INTERMEDIATES FOR USE THEREIN SPURCOURT LIMITED (GB) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160327-A1 Modified Malonate Derivatives ME2, ME3, ME1 ALDH1A1 784/4885NPSR1 4840/4885NPC1 4164/4885
US-20140088097-A1 HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF SCNN1B, SCNN1A, TRPV1 ALDH1A1 1172/4885NPSR1 1889/4885NPC1 690/4885
US-20040073038-A1 Process of preparing paroxetine and intermediates for use therein CYP2D6, CYP2C19, CYP2B6 ALDH1A1 602/4885NPSR1 259/4885NPC1 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.